Opdivo: Clinical Trials

324 trials of Opdivo, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

131 completed, 65 terminated, 57 active not recruiting, 33 recruiting. 324 Phase 1, 134 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1324Completed 131, Terminated 65, Active not recruiting 57, Recruiting 33, Withdrawn 17, Unknown 13, Suspended 6, Not yet recruiting 2
Phase 2134Completed 56, Terminated 30, Active not recruiting 18, Recruiting 13, Unknown 9, Withdrawn 6, Suspended 2

Follow Opdivo: new trials by email Literature Review of Opdivo trials Research Report on Opdivo

Trials (filtered) newest first · largest first

All 324 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1Not yet recruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company1122026-12-312026-09-30
Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older
Anakinra, Biospecimen Collection, Computed Tomography - Melanoma
Phase 1Not yet recruitingUniversity of Southern California402026-11-012026-09-24
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab - Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
Phase 1RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins272026-10-282026-10-30
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Bmab1700, Opdivo - Melanoma
Phase 1RecruitingBiocon Biologics UK PLC1202026-09-092026-11-06
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
Bevacizumab, Ipilimumab, Nivolumab - Melanoma Brain Metastases
Phase 1 / Phase 2RecruitingMelanoma and Skin Cancer Trials Limited462026-08-312026-10-13
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept - Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Phase 1 / Phase 2RecruitingWashington University School of Medicine262026-07-072026-07-10
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
Pazopanib, Trabectedin, Ipilimumab - Soft Tissue Sarcomas
Phase 1RecruitingM.D. Anderson Cancer Center182026-06-122026-08-06
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma
Phase 1RecruitingCity of Hope Medical Center332026-03-232026-07-16
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody - Prostate Cancer Patients, Non-castrate Prostate Cancer
Phase 1RecruitingUniversity of Wisconsin, Madison142026-03-032026-03-11
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
Cabozantinib, Nivolumab - Clear Cell Renal Cell Carcinoma
Phase 1RecruitingM.D. Anderson Cancer Center162026-02-122026-08-11
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Zanzalintinib, Ipilimumab, Nivolumab - Metastatic Soft-tissue Sarcoma
Phase 1SuspendedWashington University School of Medicine182026-01-052026-09-04
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
HLX13, Yervoy, OPDIVO - Hepatocellular Carcinoma (HCC)
Phase 1RecruitingShanghai Henlius Biotech2462025-11-252026-03-16
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Aerosol Sargramostim, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung
Phase 1WithdrawnMayo Clinic2025-10-282025-08-07
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma
Phase 1 / Phase 2RecruitingUniversity of Michigan Rogel Cancer Center552025-08-152026-07-31
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
BMS-986488, Adagrasib, Cetuximab - Advanced Malignant Tumors
Phase 1RecruitingBristol-Myers Squibb4372025-03-252026-07-29
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
BMS-986507, Osimertinib, Pembrolizumab - Lung Cancer, Breast Cancer
Phase 1 / Phase 2RecruitingBristol-Myers Squibb4162025-02-042026-09-23
Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant
Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant
Phase 1WithdrawnJonsson Comprehensive Cancer Center2024-12-012025-02-24
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
BMS-986484, Nivolumab, Oxaliplatin - Advanced Solid Tumors
Phase 1Active not recruitingBristol-Myers Squibb2132024-10-102026-04-17
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor
Phase 1 / Phase 2Recruiting7 Hills Pharma, LLC1262024-08-232026-04-13
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)162024-07-242026-10-14

Showing 20 of 324. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (52)  ·  Melanoma (48)  ·  Carcinoma, Renal Cell (38)  ·  Neoplasms (28)  ·  Neoplasm Metastasis (26)  ·  Colorectal Neoplasms (25)  ·  Carcinoma, Hepatocellular (23)  ·  Lung Neoplasms (19)  ·  Squamous Cell Carcinoma of Head and Neck (19)  ·  Carcinoma, Transitional Cell (14)  ·  Pancreatic Neoplasms (14)  ·  Breast Neoplasms (12)  ·  Ovarian Neoplasms (12)  ·  Stomach Neoplasms (12)  ·  Triple Negative Breast Neoplasms (12)

Sponsors

Bristol-Myers Squibb (41)  ·  National Cancer Institute (NCI) (27)  ·  M.D. Anderson Cancer Center (23)  ·  H. Lee Moffitt Cancer Center and Research Institute (10)  ·  City of Hope Medical Center (9)  ·  Washington University School of Medicine (9)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8)  ·  Emory University (7)  ·  Mayo Clinic (6)  ·  Jonsson Comprehensive Cancer Center (5)  ·  Northwestern University (5)  ·  St. Petersburg State Pavlov Medical University (5)  ·  Celgene (4)  ·  Dana-Farber Cancer Institute (4)  ·  Sumitomo Pharma America, Inc. (4)

Countries

United States (271)  ·  Canada (33)  ·  Australia (32)  ·  Spain (29)  ·  France (23)  ·  Italy (20)  ·  Belgium (15)  ·  Japan (14)  ·  Netherlands (14)  ·  United Kingdom (14)  ·  Germany (12)  ·  Argentina (11)  ·  Chile (10)  ·  Poland (10)  ·  Russia (7)

Top investigators

Sumanta K Pal (4)  ·  Boris V Afanasyev, Ph.D (2)  ·  Catherine S Diefenbach (2)  ·  Curtis Chin, MD (2)  ·  David Bond, MD (2)  ·  Eric Jonasch, MD (2)  ·  Erlinda M Gordon, MD (2)  ·  Evan J Lipson (2)  ·  Helen Heslop, MD (2)

Results publications

PMID 31401903, PMID 34272087, PMID 34385708, PMID 39462179, PMID 22590666, PMID 24089446, PMID 25482239, PMID 26773716, PMID 27269947, PMID 27410923, PMID 27528724, PMID 29257710, PMID 29490632, PMID 29628312, PMID 29692997, PMID 31105267, PMID 31400961, PMID 31538815, PMID 31563517, PMID 32192573, PMID 32303612, PMID 32478814, PMID 32489249, PMID 32503469, PMID 32503950, PMID 32508818, PMID 32616557, PMID 32853585, PMID 32915679, PMID 33002543, PMID 33046870, PMID 33062947, PMID 33064988, PMID 33148673, PMID 33203665, PMID 33277223, PMID 33294862, PMID 33387490, PMID 33507454, PMID 33535600, PMID 33608377, PMID 33677480, PMID 33720354, PMID 33757459, PMID 33786583, PMID 33892407, PMID 33909232, PMID 33963014, PMID 34347542, PMID 34543871

NIH funding

2018 (11), P30CA033572 (8), 2016 (5), 2017 (5), P30CA060553 (5), P30CA138292 (5), UM1CA186691 (4), 2015 (3), 2023 (3), P30CA014089 (3), UM1CA186689 (3), 2019 (2), 2025 (2), P30CA006516 (2), P30CA015704 (2)